The target INR range for patients on warfarin therapy varies depending on their condition but is typically between 2.0 and 3.0.

Frequency of testing depends on individual patient needs, but initially, it may be done weekly or bi-weekly until stable, then less frequently thereafter.

Yes, the PT / INR Test can help diagnose various clotting disorders, including those related to liver disease or genetic clotting factor deficiencies.

Medications, dietary changes, liver function, and underlying health conditions can all influence PT / INR results.

Yes, the PT / INR Test is a safe and standard diagnostic procedure used worldwide to monitor blood clotting ability and adjust anticoagulant therapy.

It measures various lipids in the blood, including cholesterol and triglycerides, to assess cardiovascular risk.

Yes, fasting for 9-12 hours is generally required to obtain accurate fasting cholesterol levels.

It helps evaluate cardiovascular risk, diagnose lipid disorders, and monitor treatment effectiveness.

The frequency depends on individual risk factors and healthcare provider recommendations. Generally, it is recommended every 4-6 years for adults, more frequently for those with risk factors.

Benefits include effective treatment of bladder cancer, relief from severe bladder dysfunction, and potential improvement in quality of life.